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Abstract
Chemistry Central is a new open access website for chemists publishing peer-reviewed research
in chemistry from a range of open access journals. A new addition, Chemistry Central Journal, will
cover all of chemistry and will be broken down into discipline-specific sections, and Im delighted
that Medicinal Chemistry will be a key discipline in this new journal.
The open access model for scientific publication contin-
ues to gain support and is already well established in
many areas of science and mathematics. BioMed Central
[1] has been at the forefront of this movement and now
has an impressive portfolio of over 60 journals [2]. In
addition there are over 100 independent journals sup-
ported by BioMed Central [3]. The importance to the sci-
entific community is underlined by the fact that Thomson
Scientific (ISI) tracks many BioMed Central titles, and sev-
eral have already achieved impressive Impact Factors [4].
In addition, all BioMed Central journal articles are tracked
by Scopus [5] and Google Scholar [6]. Studies [7] suggest
that open-access articles across a number of disciplines
have a greater impact than those that are not freely availa-
ble, and wider indexing might be expected to increase vis-
ibility and impact.
Chemistry Central [8] is a new open access website for
chemists publishing peer-reviewed research in chemistry
from a range of open access journals. A new addition,
Chemistry Central Journal [9], will cover all of chemistry
and will be broken down into discipline-specific sections,
and I'm delighted that Medicinal Chemistry will be a key
discipline in this new journal.
In many ways medicinal chemistry provides a bridge
between biology and chemistry, identifying novel com-
pounds that modulate a biological response and thuspro-
viding the tools to investigate biological processes,
subsequently optimizing those compounds to avoid
undesired interactions with other biological systems. The
challenge of bringing a novel drug molecule to market has
increased considerably over the last two decades. To meet
this challenge the medicinal chemist's toolbox has
expanded over the years to include, high-throughput
screening, computer-aided design, X-ray crystallography,
target protein mutagenesis, combinatorial and automated
chemistry, QSAR, chemical property calculations, compu-
tational data analysis, high-throughput ADME assays. All
of which would be suitable topics for the new Medicinal
Chemistry section of the Chemistry Central Journal.
Given the vast range of potential topics I thought I'd per-
haps highlight two for detailed comment. The cost and
time taken to develop drugs has increased enormously
over the last three decades [10] with the current average
time taken for discovery and development being 9-12
years and the costs predicted to top $1 billion. It is thus
imperative that compounds brought forward do not fail
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in late stage development and the two features that have a
major impact are pharmacokinetics and toxicity. In 1997
Lipinski published a key paper identifying molecular fea-
tures that appear to be found in orally available drugs [11]
the Lipinski "rule of five" has since become the yardstick
by which potential development compounds are judged.
It has also spawned an ongoing analysis of molecular
properties and how they might be used to improve the
drug discovery process from lead identification to drug
development.
The Human Ether-a-go-go gene (HERG) encodes a potas-
sium ion channel responsible for the repolarizing current
in the cardiac action potential (the HERG gene is related
to the Ether-a-go-go gene found in the Drosophila fly.
When flies with mutations in this gene are anaesthetized
with ether, their legs start to shake, like the dancing then
popular at the Whisky A Go-Go nightclub in West Holly-
wood, California. Ether-a-go-go was named in the 1960s
by William D. Kaplan). A number of drugs have been
shown to bind to this channel causing decreased channel
function and causing QT prolongation and fatal cardiac
arrhythmias. In 2000 Mitcheson et al published a seminal
paper in PNAS giving a molecular insight into how struc-
turally unrelated molecules might block the ion channel
[12]. This has lead to a number of predictive pharmacoph-
ore models or docking studies trying to eliminate this
unwanted activity. Many of these studies would benefit
from open access to larger data sets to enable refinement
of the models and this journal could potentially provide
such information.
Online publishing offers many practical advantages
beyond electronic handling of manuscripts right up to the
point of publication. Online formats aid the support for
the use of color to create high quality figures, graphs, and
color images. In addition many technologies not available
in print-only formats can be explored such as hyperlink-
ing, video files, and interactive graphics and molecular
superimpositions. Figures will be able to be submitted in
ChemDraw (.CDX) or ISIS/Draw (.TGF) file formats. All
articles will be deposited in PubMed Central [13], and will
therefore be automatically linked into PubChem [14],
based on the chemical substances that they mention.
Additional information such as experimental or spectro-
scopic data assisting the reader can, and will, be provided
liberally and could of course be linked electronically to
structures within the document. The ready availability of
supporting data should make this an invaluable data store
for structure activity information for future work.
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